


DECEMBER 2020

# Recommendations for the Management of Colon and Rectal Cancer during the COVID-19 Pandemic



Working Group Committee Members: Al B. Benson, Brian C. Brajcich, Gerald Gantt Jr., Oliver S. Eng, Robert de W. Marsh, Ryan P. Merkow, Mary F. Mulcahy, Brenda O'Brien, Blaise N. Polite, Benjamin D. Shogan

# The Illinois Cancer Collaborative (ILCC)

The Illinois Cancer Collaborative (ILCC) is a first-of-its kind, multidisciplinary statewide partnership of Illinois hospitals working together to improve the safety and quality of care for cancer patients across Illinois during, and after, the COVID-19 pandemic. Our vision is to engage providers to deliver patient-centered, high-quality cancer care across Illinois. If you are interested in joining the ILCC, please visit our webpage at [ilcancer.org](http://ilcancer.org) and contact us at [info@ilcancer.org](mailto:info@ilcancer.org).

## The ILCC COVID-19 Working Groups and Consensus Guidelines

Providers and institutions throughout Illinois are experiencing difficulty with the lack of evidence and recommendations from numerous sources for cancer care during the COVID-19 pandemic. In response, the ILCC convened three multidisciplinary working groups of experts to pool their experience, expertise, and knowledge in regard to safe and optimal care of cancer patients during the pandemic. The results are the ILCC Consensus Guidelines for COVID-19 Cancer Care in three areas: Colorectal Cancer, Lung Cancer, and Visitor Policies for Ambulatory Cancer Care. The goal of these guidelines is to provide a single source for hospitals, clinics, and practices to support safe and optimal care for cancer patients statewide during this unprecedented pandemic.

These guidelines represent the consensus recommendations of the members of the Illinois Cancer Collaborative COVID-19 Operations Working Group and do not represent endorsement or approval by their individual institutions.

# CONTENTS



---

**04**

EVIDENCE REVIEW

---

**06**

RECOMMENDATIONS

06.....MANAGEMENT OF LOCOREGIONAL COLON  
CANCER IF SURGERY IS DELAYED

07.....MANAGEMENT OF LOCOREGIONAL RECTAL  
CANCER IF SURGERY IS DELAYED

08.....MANAGEMENT OF METASTATIC COLORECTAL  
CANCER IF SURGERY IS DELAYED

09.....PATIENT CARE COORDINATION

---

**10**

APPENDIX

10.....REFERENCES

11.....MEMBERS

---

# Evidence Review

## Risk of delayed surgical treatment of colon cancer

- A single center study showed that a 30, 60, 90, or 120-day period from diagnosis to surgical treatment of colorectal cancer was not associated with worse survival.[5]
- A systematic review of 5 studies with diagnosis-to-surgery intervals up to 56 days concluded that there was no association between delay in surgery and survival in colon cancer.[6]
- A study showed that patients with stage I to III colon cancer who had primary elective surgery >40 days after diagnosis experienced reduced survival. Each 14-day increase in the interval from diagnosis to surgery was associated with a 6% increase in the hazard of death.[7]

## Risks of delayed surgical treatment of rectal cancer

- A delay of >60 days from onset of symptoms to radiation or surgical treatment was associated with lower survival.[8]
- A review suggested that no association was seen between treatment delay and survival among patients with rectal cancer.[9]
- An interval of >6-8 weeks from the completion of neoadjuvant therapy to surgery was associated with improved rates of pathologic complete response but not with overall survival.[10]
- A watch-and-wait approach for patients with rectal cancer who had complete clinical response to neoadjuvant therapy was shown to result in worse survival than total mesorectal excision but can be considered in selected patients.[11]

## Neoadjuvant regimens for colon and rectal cancer

- The feasibility phase of the FOxTROT trial suggested that neoadjuvant chemotherapy is safe for locally advanced, operable (T3-T4a, N0-2, M0) colon cancer.[12] The preliminary results of the multicenter trial showed that neoadjuvant therapy reduced surgical complications but did not affect survival at 2 years.[13]
- Neoadjuvant chemoradiation is the standard of care for high-risk clinical stage II-III rectal cancer.[14]
- Three clinical trials have demonstrated no difference in outcomes for short vs. standard course neoadjuvant radiotherapy for rectal cancer.[15-17]

# Recommendations

---

## Management of locoregional colon cancer if surgical resources are limited

### ASYMPTOMATIC PRIMARY

#### CLINICAL STAGE I-II

- Consider delaying all therapy if inpatient resources are expected to become available within 4 weeks.
- In select cases, particularly T3-4a disease, neoadjuvant chemotherapy may be considered. The length of therapy should be tailored to the clinical stage and anticipated ability to offer surgical resection. The total length of therapy can be modified based on pathologic stage. A capecitadine/oxaliplatin (CAPOX) regimen is preferable to leucovorin/5-fluorouracil/oxaliplatin (FOLFOX).

#### CLINICAL STAGE III

- Consider neoadjuvant chemotherapy. The length of therapy should be tailored to the clinical stage and anticipated ability to offer surgical resection. The total length of systemic therapy can be modified based on pathologic stage and CAPOX is preferable to FOLFOX.

### SYMPTOMATIC PRIMARY

- If hospital resources are severely limited, consider alternatives to definitive resection in patients at high risk of complications, need for intensive care, or prolonged hospitalization. Alternatives should be determined on a case-by-case basis but may include endoluminal stent placement in left-sided tumors, fecal diversion, or resection without immediate anastomosis.
- If symptoms are not amenable to a temporizing intervention, definitive surgery should be offered.

# Management of locoregional rectal cancer if surgical resources are limited

## ASYMPTOMATIC PRIMARY

### CLINICAL STAGE I

- Consider delaying all therapy if inpatient resources will become available within 4 weeks.
- In select cases, neoadjuvant chemoradiation may be considered.
- The duration of chemotherapy should be tailored to the clinical stage and anticipated ability to offer surgical resection. The total length of therapy can be modified based on pathologic stage, and CAPOX is preferable to FOLFOX.
- Short course radiation (5 doses of 5 Gy) should be considered to minimize hospital exposure.
- At experienced centers, a watch-and-wait approach for select patients with complete clinical response to neoadjuvant chemoradiation can be considered.

### CLINICAL STAGE II-III

- Neoadjuvant chemoradiation should be administered prior to surgical resection for stage II-III rectal cancers.
- The length of therapy should be tailored to the clinical stage and anticipated ability to offer surgical resection. The total length of therapy can be modified based on pathologic stage.
- CAPOX is preferable to FOLFOX and should be administered prior to radiation.
- Short course radiation (5 doses of 5 Gy) should be considered to minimize hospital exposure.
- At experienced centers, a watch-and-wait approach for select patients with complete clinical response to neoadjuvant chemoradiation can be considered.

## SYMPTOMATIC PRIMARY

- If hospital resources are severely limited, consider alternatives to definitive resection in patients at high risk of complications, need for intensive care, or prolonged hospitalization. Alternatives should be determined on a case-by-case basis but may include fecal diversion or resection without immediate anastomosis.
- If symptoms are not amenable to a temporizing intervention, then definitive surgery and/or radiation should be offered.
- Stenting is not recommended as a temporizing measure for rectal cancers.

# Management of metastatic colorectal cancer if surgical resources are limited

---

- If curative intent surgery is possible (e.g., isolated metastatic liver and/or pulmonary disease, peritoneal disease), decisions about treatment should incorporate the extent of disease, expected surgical morbidity, risk of disease progression without intervention, and availability of inpatient resources.
- If surgery is not indicated, less invasive alternative therapies including Y-90 radioembolization or stereotactic body radiation therapy should be considered.

---

# Patient Care Coordination

Patients with colorectal cancer should have initial telehealth appointments with the following providers to ensure that (1) treatment can proceed quickly after care is resumed, and (2) patients will be known to their providers if emergent intervention is needed:

- Primary care practitioner
- General surgeon, colorectal surgeon, or surgical oncologist
- Gastroenterologist
- Medical oncologist (*if applicable*)
- Radiation oncologist (*if applicable*)
- Medical geneticist (*if applicable*)

A protocol should be developed to ensure that patients with newly diagnosed colorectal cancer are scheduled for initial appointments with these providers.

If no immediate treatment is planned, a process should be developed to maintain contact with each patient to ensure that they are not lost to follow-up and can resume treatment when resources permit.

Patients should be instructed how to perform simple tasks, such as disconnecting their chemotherapy pump at home, to minimize the need for healthcare encounters which risk exposure.

# Appendix

## References

1. Czeisler ME, Marynak K, Clarke KEN, et al. Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns - United States, June 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(36):1250-1257.
2. Baum A, Kaboli PJ, Schwartz MD. Reduced In-Person and Increased Telehealth Outpatient Visits During the COVID-19 Pandemic. *Ann Intern Med.* 2020.
3. Disis ML. Oncology and COVID-19. *JAMA.* 2020;324(12):1141-1142.
4. Illinois Cancer Collaborative. <http://ilcancer.org/>. Published 2020. Accessed November 30, 2020.
5. Wanis KN, Patel SVB, Brackstone M. Do Moderate Surgical Treatment Delays Influence Survival in Colon Cancer? *Dis Colon Rectum.* 2017;60(12):1241-1249.
6. Hangaard Hansen C, Gogenur M, Tvilling Madsen M, Gogenur I. The effect of time from diagnosis to surgery on oncological outcomes in patients undergoing surgery for colon cancer: A systematic review. *Eur J Surg Oncol.* 2018;44(10):1479-1485.
7. Grass F, Behm KT, Duchalais E, et al. Impact of delay to surgery on survival in stage I-III colon cancer. *Eur J Surg Oncol.* 2020;46(3):455-461.
8. Iversen LH, Antonsen S, Laurberg S, Lautrup MD. Therapeutic delay reduces survival of rectal cancer but not of colonic cancer. *Br J Surg.* 2009;96(10):1183-1189.
9. Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguiló A. Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. *Eur J Cancer.* 2007;43(17):2467-2478.
10. Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies. *Ann Surg.* 2016;263(3):458-464.
11. Smith JJ, Strombom P, Chow OS, et al. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. *JAMA Oncol.* 2019;5(4):e185896.
12. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. *Lancet Oncol.* 2012;13(11):1152-1160.
13. Seymour MT, Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. *Journal of Clinical Oncology.* 2019;37(15\_suppl):3504-3504.
14. Network NCC. Rectal Cancer (version 6.2020). [https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf). Accessed November 30, 2020.
15. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. *Radiother Oncol.* 2004;72(1):15-24.
16. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. *J Clin Oncol.* 2012;30(31):3827-3833.
17. Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. *Lancet Oncol.* 2017;18(3):336-346.

# Members

Al B. Benson, MD

Northwestern University Feinberg School of Medicine

Brian C. Brajcich, MD, MS

The Illinois Cancer Collaborative

Gerald Gantt, Jr., MD

University of Illinois College of Medicine

Oliver S. Eng, MD

University of Chicago

Robert de W. Marsh, MD

NorthShore University HealthSystem, University of Chicago

Ryan P. Merkow, MD, MS

The Illinois Cancer Collaborative

Mary F. Mulcahy

Northwestern University Feinberg School of Medicine

Brenda O'Brien

Northwest Community Hospital

Blase N. Polite, MD, MPP

University of Chicago

Benjamin D. Shogan, MD

University of Chicago